Showing 7331-7340 of 8827 results for "".
- Two New Studies Highlight the Efficacy and Safety Profile of Revance's DAXXIFYhttps://practicaldermatology.com/news/two-new-studies-highlights-the-efficacy-and-safety-profile-of-daxxify/2461360/Glabellar injection of DAXXIFY show a positive effect on eyebrow position and a high response rate and duration of effect ≥24 weeks across all age and race subgroups, according to two new studies in the Aesthetic Surgery Journal. “The newly released pu
- FDA Clears CellFX System for the Treatment of SHhttps://practicaldermatology.com/news/fda-clears-cellfx-system-for-the-treatment-of-sh/2461358/The U.S. Food and Drug Administration (FDA) granted Pulse Bioscience’s CellFX System (FDA) 510(k)marketing clearance for the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-II. This specific indication clearance enhances the CellFX
- Spotlight On: Honey and Its Role in Wound Healinghttps://practicaldermatology.com/news/spotlight-on-honey/2461353/Honey may play a role in wound healing due to its antimicrobial and tissue-regenerative properties, according to scientists from the University of Manchester. Their review of more than 250 articles spans 85 years -with oldest article from 1937- is published in the journal Pharmaceu
- Meet EMFACE From BTLhttps://practicaldermatology.com/news/meet-emface-from-btl/2461350/BTL is taking on the minimally invasive facial aesthetic category with the launch of EMFACE. Emface simultaneously emits both
- Baby Dove Doubles Down Efforts to Close the Maternal Care Gap with #DearDoula and Greater Investment in Black Birth Equity Fundhttps://practicaldermatology.com/news/baby-dove-doubles-down-efforts-to-close-the-maternal-care-gap-with-deardoula-and-greater-investment-in-black-birth-equity-fund/2461342/Baby Dove is expanding the Black Birth Equity Fund, launching a new informative series called #DearDoula, and reinforcing existing strategic partnerships to help close the significant gap in care and health outcomes for Black mothers and their babies. "As a brand that encourages al
- Dermatologists Must Help Fight Climate Changehttps://practicaldermatology.com/news/dermatologists-must-help-fight-climate-change/2461339/Dermatologists should engage more meaningfully on key climate issues and to move beyond discussions of the skin-related impacts of climate change, according to a commentary in the International Journal of Dermatology.</
- EADV News: ‘Healthy’ Suntan Myths Persist in Europehttps://practicaldermatology.com/news/eadv-news-healthy-suntan-myths-persist-in-europe/2461338/Fully eight in 10 Europeans believe tans are attractive with almost as many (73%) saying tans are healthy, according to a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. Results from a survey, conducted by La Roche-Posay Laboratoires and
- Dermalogica Gives Back: Brand Launches Grant Program to Empower the Next Generation of Industry Proshttps://practicaldermatology.com/news/dermalogica-gives-back-brand-launches-grant-program-to-empower-the-next-generation-of-industry-pros/2461337/Dermalogica is offering a new grant program for non-profit organizations that help give greater access to skillset training in the United States. The grant program is now accepting applications and supports education, mentorship, and skills training for non-profits training therap
- Daxxify from Revance Gets FDA Greenlighthttps://practicaldermatology.com/news/daxxify-from-revance-gets-fda-greenlight/2461331/Daxxify™ (DaxibotulinumtoxinA-lanm) from Revance is FDA approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults. Daxxify is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum
- EADV News: Tape Strip Test May Predict Eczema Risk in Babieshttps://practicaldermatology.com/news/eadv-news-tape-strip-test-may-predict-eczema-risk-in-babies/2461329/An immune biomarker in newborns may predict the subsequent onset and severity of paediatric atopic eczema, according to a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. The Barrier dysfunction in Atopic newBorns (BABY) study analyzed a c